ABCAM Plc Notice of Results (6507O)
February 10 2016 - 5:59AM
UK Regulatory
TIDMABC
RNS Number : 6507O
ABCAM Plc
10 February 2016
10 February 2016
ABCAM PLC
("Abcam" or "the Company")
Notice of Interim Results
Cambridge UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools, expects to announce its
interim results for the six month period ended 31 December 2015 on
7 March 2016. A briefing for analysts will be held at 09.30 GMT on
7 March at the offices of FTI Consulting, 200 Aldersgate,
Aldersgate Street, London, EC1A 4HD. A live audio webcast and slide
presentation of this event will also be available at
www.abcamplc.com.
+ 44 (0) 1223
Abcam 696 000
Alan Hirzel, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Julia Wilson - Investor Relations
J.P.Morgan Cazenove - Nominated + 44 (0) 20
Adviser & Corporate Broker 7742 4000
James Mitford / Alex Bruce
FTI Consulting
Ben Atwell / Brett Pollard / Natalie +44 (0) 20
Garland-Collins 3727 1000
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Two-thirds of the world's 750,000 life science researchers use
Abcam's affinity binders, reagents, biomarkers and assays and the
company's products are mentioned in over 20,000 of the 56,000
peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's ten offices are located in the world's leading life
science research hubs, enabling local services and multi-language
support. Founded in 1998 and headquartered in Cambridge, UK, the
Company now employs over 800 people and sells to more than 100
countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBGGDDRUBBGLG
(END) Dow Jones Newswires
February 10, 2016 05:59 ET (10:59 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024